Swedish Orphan Biovitrum AB (MEX:SOBI N) Market Cap: MXN297,720 Mil (As of Jul. 06, 2026)


MEX:SOBI N Swedish Orphan Biovitrum AB MEX:SOBI N
85 GF Score
Price MXN523.55
GF Value MXN376.05
! 6 Warning Signs
View Full Analysis

What is Swedish Orphan Biovitrum AB Market Cap?

Swedish Orphan Biovitrum AB MEX:SOBI N 85 Market Cap is MXN297,720 Mil as of Jul. 06, 2026. GuruFocus rates MEX:SOBI N with a GF Score™ of 85/100 and a GF Value™ of MXN376.05. The stock has 6 warning signs investors should review. Among 1,024 Drug Manufacturers companies, Swedish Orphan Biovitrum AB ranks better than 96.48% on this metric.

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Swedish Orphan Biovitrum AB's share price for the quarter that ended in Mar. 2026 was MXN523.55284. Swedish Orphan Biovitrum AB's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 346 Mil. Therefore, Swedish Orphan Biovitrum AB's market cap for the quarter that ended in Mar. 2026 was MXN181,068 Mil.

Swedish Orphan Biovitrum AB's quarterly market cap increased from Sep. 2025 (MXN180,446 Mil) to Dec. 2025 (MXN180,972 Mil) and increased from Dec. 2025 (MXN180,972 Mil) to Mar. 2026 (MXN181,068 Mil).

Swedish Orphan Biovitrum AB's annual market cap increased from Dec. 2023 (MXN177,881 Mil) to Dec. 2024 (MXN179,811 Mil) and increased from Dec. 2024 (MXN179,811 Mil) to Dec. 2025 (MXN180,972 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Swedish Orphan Biovitrum AB's Enterprise Value for Today is MXN330,297 Mil.


Swedish Orphan Biovitrum AB  (MEX:SOBI N) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the company’s debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.


Swedish Orphan Biovitrum AB Market Cap Related Terms


Swedish Orphan Biovitrum AB Market Cap Historical Data

* Premium members only.

The historical data trend for Swedish Orphan Biovitrum AB's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Swedish Orphan Biovitrum AB Market Cap Chart

Swedish Orphan Biovitrum AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Market Cap
Get a 7-Day Free Trial Premium Member Only Premium Member Only 161,775.73 162,253.21 177,880.74 179,810.56 180,971.80

Swedish Orphan Biovitrum AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Market Cap Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 179,817.89 180,420.50 180,445.63 180,971.80 181,068.13

MEX:SOBI N vs ZTS, UTHR: Market Cap Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Swedish Orphan Biovitrum AB's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Swedish Orphan Biovitrum AB Market Cap vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Swedish Orphan Biovitrum AB's Market Cap distribution charts can be found below:

* The bar in red indicates where Swedish Orphan Biovitrum AB's Market Cap falls into.


MEX:SOBI N
85GF Score
Swedish Orphan Biovitrum AB MEX:SOBI N
Market Cap is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Swedish Orphan Biovitrum AB Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

Swedish Orphan Biovitrum AB's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as

Market Cap (A: Dec. 2025 )=Share Price (A: Dec. 2025 )*Shares Outstanding (EOP) (A: Dec. 2025 )
=MXN523.55284*345.661
=MXN180,972

Swedish Orphan Biovitrum AB's Market Cap for the quarter that ended in Mar. 2026 is calculated as

Market Cap (Q: Mar. 2026 )=Share Price (Q: Mar. 2026 )*Shares Outstanding (EOP) (Q: Mar. 2026 )
=MXN523.55284*345.845
=MXN181,068

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Market Cap →
What does a Market Cap of MXN297,720 Mil mean?
Swedish Orphan Biovitrum AB (MEX:SOBI N) has a Market Cap of MXN297,720 Mil as of Jul. 06, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Swedish Orphan Biovitrum AB and its competitors. According to the industry distribution chart, Swedish Orphan Biovitrum AB ranks #36 out of 1024 companies in the Drug Manufacturers industry, placing it in the top 3.5%.
Is Swedish Orphan Biovitrum AB's Market Cap too high?
Swedish Orphan Biovitrum AB's current Market Cap is MXN297,720 Mil. Based on the distribution chart, Swedish Orphan Biovitrum AB ranks #36 out of 1024 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Swedish Orphan Biovitrum AB has a GF Score™ of 85/100, reflecting its overall financial health beyond just this single metric.
How does Swedish Orphan Biovitrum AB's Market Cap compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Swedish Orphan Biovitrum AB ranks #36 out of 1024 companies for Market Cap. This places Swedish Orphan Biovitrum AB in the top 4% of its industry — outperforming the majority of peers. The industry median Market Cap is 214.89. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Drug Manufacturers company?
The median Market Cap among Drug Manufacturers companies is 214.89, based on 1,024 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Swedish Orphan Biovitrum AB and its competitors. For the Drug Manufacturers industry, the median Market Cap is 214.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Swedish Orphan Biovitrum AB's current Market Cap is MXN297,720 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Swedish Orphan Biovitrum AB stock overvalued right now?
Swedish Orphan Biovitrum AB (MEX:SOBI N) has a current Market Cap of MXN297,720 Mil. The stock's GF Value™ is MXN376.05, compared to a current price of MXN523.55 — trading 39.2% above its estimated fair value. The current Market Cap is MXN297,720 Mil. Swedish Orphan Biovitrum AB's overall GF Score™ is 85/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Swedish Orphan Biovitrum AB (MEX:SOBI N), the current Market Cap is MXN297,720 Mil as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Swedish Orphan Biovitrum AB (MEX:SOBI N) Overvalued in 2026?

Based on GuruFocus' analysis, Swedish Orphan Biovitrum AB stock appears to be overvalued. The current stock price of MXN523.55 is trading 39.2% above its estimated GF Value™ of MXN376.05.

Key valuation signals for MEX:SOBI N:

  • Market Cap: MXN297,720 Mil
  • GF Value™: MXN376.05 vs. price of MXN523.55 (39.2% above fair value)
  • GF Score™: 85/100 with 6 warning signs

No single metric tells the full story. See the MEX:SOBI N stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Swedish Orphan Biovitrum AB Business Description

Address Norra Stationsgatan 93A, Stockholm, SWE, SE-112 76
Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) in 2006 on long-acting hemophilia factor replacement programs. Biovitrum acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched hemophilia products Alprolix and Eloctate in Europe in 2016, and Altuvoct in 2024. Sobi has been building its immunology pipeline (rare-disease drug Gamifant, US rights to RSV antibodies Synagis and Beyfortus, gout drugs, complement drug Aspaveli) and a broader hematology pipeline (thrombocytopenia drug Doptelet, blood cancer drug Zynlonta, myelofibrosis drug Vonjo).
85GF Score

Get the complete analysis for MEX:SOBI N

Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN523.55
Price
MXN376.05
GF Value